MSH|^~\&|MIC|ARH|||201910291753||ORU^R01|4093276|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34602^MIC|00026590^19:X0000059R^MIC^19:X59^34602|800.5000^MRSA^MRSA culture^^^13317-3||201910290807|201910290803|||||||201910290803|Nares - bilateral^^^|||||||||MB|F||||
OBX|1|CE|800.5000^MRSA^MRSA culture^^^13317-3^O:MRSA|1.1|MRSA^Staphylococcus aureus-MRSA||||||F|||201910291753
OBX|2|ST|800.5000^MRSA^MRSA culture^^^13317-3^P:AMT|1.1|||||||F|||201910291753
OBX|3|ST|800.5000^MRSA^MRSA culture^^^13317-3^R:4|1.1|4+||||||F|||201910291753
OBR|2||00026590^19:X0000059R^MIC^19:X59^34602|913.2500^P580^Vitek P580 Sensitivity^^^29576-6||201910290807|201910290803|||||||201910290803|Nares - bilateral^^^|||||||||MB|F|MRSA^1.1|||34602^MIC
OBX|1|ST|101.000^CFZ^Cefazolin^^76-0^76-0|||||R|||F|||201910291753
OBX|2|ST|101.100^CF^Cephalexin^^149-5^149-5|||||R|||F|||201910291753
OBX|3|ST|200.000^AUG^Amoxicillin/Clavulanate^^20-8^20-8|||||R|||F|||201910291753
OBX|4|ST|200.600^OX^Cloxacillin^^197-4^197-4|||||R|||F|||201910291753
OBX|5|ST|400.200^E^Erythromycin^^233-7^233-7|||||S|||F|||201910291753
OBX|6|ST|400.300^CD^Clindamycin^^193-3^193-3|||||S|||F|||201910291753
OBX|7|ST|600.000^TS^Trimethoprim/sulfamethoxazole^^516-5^516-5|||||S|||F|||201910291753
OBX|8|ST|700.000^TE^Tetracycline^^496-0^496-0|||||S|||F|||201910291753
OBX|9|ST|700.100^DOX^Doxycycline^^225-3^225-3|||||S|||F|||201910291753
OBX|10|ST|800.000^VA^Vancomycin^^524-9^524-9|||||S|||F|||201910291753

MSH|^~\&|MIC|ARH|||201910291758||ORU^R01|4093277|D|2.3|||AL|NE
PID|1||AB00008278|AB8184|LABTESTBEAGLE^LUMED^||19700302|F||||||||||AB000558/19|9874974645
OBR|1|34603^MIC|00026590^19:MT0000181R^MIC^19:MT181^34603|700.1950^CDT^C. difficile Assay^^^XXX-2144||201910290807|201910290803|||||||201910290803|Stool^^^|||||||||MB|F||||
OBX|1|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Patients positive for the C. difficile toxin B gene should||||||F|||201910291758
OBX|2|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|not have a test of cure as the test may remain positive for||||||F|||201910291758
OBX|3|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|months after symptom resolution.||||||F|||201910291758
OBX|4|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Approximately 25% of adequately treated patients will have a||||||F|||201910291758
OBX|5|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|relapse of C. difficile disease. Repeat C. difficile testing||||||F|||201910291758
OBX|6|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|is not helpful.||||||F|||201910291758
OBX|7|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|||||||F|||201910291758
OBX|8|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|A copy of these results has been sent to Infection||||||F|||201910291758
OBX|9|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Prevention and Control.||||||F|||201910291758
OBX|10|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|||||||F|||201910291758
OBX|11|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|For mild or first recurrent Clostridium difficile associated||||||F|||201910291758
OBX|12|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|diarrhea in adults, treatment with oral vancomycin is now||||||F|||201910291758
OBX|13|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|considered more effective than metronidazole.  Consult||||||F|||201910291758
OBX|14|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|Infectious Disease Society of America (IDSA) 2017||||||F|||201910291758
OBX|15|ST|700.2060^CDTPCR R^C. difficile toxin B gene^^74822-8^74822-8|1|C.difficile guideline or UpToDate.||||||F|||201910291758